Welcome to our dedicated page for Nutriband SEC filings (Ticker: NTRB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nutriband Inc’s mission to curb opioid abuse with AVERSA taste-aversion patches makes its regulatory story more technical than most small-cap pharma peers. Decoding a single 10-K to see how Kindeva production agreements affect margins, or finding child-safety trial data buried in a 10-Q, can absorb an analyst’s entire afternoon. Add the need to monitor Nutriband insider trading Form 4 transactions after each patent update, and the workload multiplies quickly. That’s the challenge our Filings hub addresses.
Our platform delivers Nutriband SEC filings explained simply. Stock Titan’s AI reads every Nutriband quarterly earnings report 10-Q filing the moment it hits EDGAR, highlights revenue shifts, and attaches plain-English notes. Real-time alerts surface Nutriband Form 4 insider transactions real-time alongside a concise Nutriband earnings report filing analysis, so you see patterns in minutes, not days. Even the dense Nutriband proxy statement executive compensation tables are broken down with side-by-side visuals.
Want deeper detail? Start by reviewing the Nutriband annual report 10-K simplified summary, then jump to a tagged list of Nutriband 8-K material events explained within hours of release. Our AI also pinpoints Nutriband executive stock transactions Form 4 to show whether management is buying additional shares as opioid-abuse trials advance. By understanding Nutriband SEC documents with AI, professionals gain faster clarity on revenue drivers, IP longevity, and risk disclosures—without sifting through hundreds of pages.
NutriBand (NTRB) CFO Gerald Goodman filed a Form 5 for the fiscal year ended 01/31/2025, reporting year-end holdings and prior transactions under Section 16. The filing shows 66,085 shares of common stock beneficially owned at fiscal year-end, held directly.
Reported transactions include: acquisition of 60,085 common shares at $1.93 on 10/27/2023; a warrant at $1.93 tied to 60,085 underlying shares with an expiration date of 10/27/2026; a stock option grant for 75,000 shares at $1.93 on 03/19/2024 expiring 03/19/2027; and a stock option grant for 17,667 shares at $7.34 on 01/23/2025 expiring 01/23/2028. Ownership is indicated as direct for the securities listed.
Nutriband Inc. filed a prospectus supplement updating its 424(b)(3) prospectus for public warrants covering up to 910,904 shares of common stock. The outstanding warrants stem from the company’s October 2021 unit offering and are immediately exercisable at an adjusted exercise price of $6.43 per share.
As of October 19–20, 2025, 910,904 warrants remained outstanding and trade on Nasdaq as NTRBW. On October 17, 2025, the last reported sale prices were $7.48 per share for common stock and $2.50 per warrant. Shares outstanding were 12,034,883 as of September 8, 2025; this is a baseline figure, not the amount being offered.
The supplement also incorporates the company’s latest Form 10-Q, which showed revenue of $622,452 for the quarter ended July 31, 2025 and cash and cash equivalents of $6,995,101 as of that date.
FAQ
What is the current stock price of Nutriband (NTRB)?
What is the market cap of Nutriband (NTRB)?
